Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Cash & Equivalents (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Cash & Equivalents for 5 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 39.74% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Sep 2025, down 39.74%, and an annual FY2024 reading of $6.2 million, down 31.36% over the prior year.
  • Cash & Equivalents was $4.1 million for Q3 2025 at Xenetic Biosciences, down from $4.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $12.0 million in Q1 2023 and bottomed at $4.1 million in Q3 2025.
  • Average Cash & Equivalents over 3 years is $7.6 million, with a median of $7.3 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 30.04% in 2024, then crashed 39.74% in 2025.
  • Year by year, Cash & Equivalents stood at $9.0 million in 2023, then plummeted by 31.36% to $6.2 million in 2024, then plummeted by 33.15% to $4.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for XBIO at $4.1 million in Q3 2025, $4.8 million in Q2 2025, and $5.2 million in Q1 2025.